Clinical Study Protocol for PENTILULA: A Phase 1/2 Study Assessing [ 177 Lu]Lu-Pentixather for Relapsed or Refractory CXCR4-Positive Acute Leukemia

医学 临床研究 急性白血病 耐火材料(行星科学) 内科学 肿瘤科 协议(科学) 临床研究阶段 临床试验 相(物质) 白血病 重症监护医学 癌症 化疗
作者
Caroline Bodet‐Milin,Faustine Lelan,Chloé François,Nicolas Chouin,Thomas Carlier,Joëlle Gaschet,Mickaël Bourgeois,Mathieu Frindel,Pierre Péterlin,Mathilde Hunault,Cécile Moluçon‐Chabrot,Pierre-Yves Dumas,Françoise Kraeber‐Bodéré,Patrice Chevallier
出处
期刊:Journal of nuclear medicine [Society of Nuclear Medicine and Molecular Imaging]
卷期号:: jnumed.126.273130-jnumed.126.273130
标识
DOI:10.2967/jnumed.126.273130
摘要

C-X-C chemokine receptor type 4 (CXCR4) inhibition may represent a new therapeutic strategy for patients with acute leukemia (AL), not only by increasing chemosensitivity but also by preventing relapse through disruption of residual leukemic cell interactions with the bone marrow niche. Radiolabeled CXCR4 ligands are available for PET imaging ([68Ga]Ga-pentixafor) and radiopharmaceutical therapy (RPT) ([177Lu]Lu-pentixather/[90Y]Y-pentixather). Early clinical experience with CXCR4-targeted RPT, together with the reported feasibility of CXCR4-targeted PET in acute myeloid leukemia, supports the development of theranostic approaches targeting the CXCR4/C-X-C motif chemokine ligand 12–defined leukemia-initiating cell niche. The objective of this study is to determine the maximum tolerated dose (MTD) of a single infusion of [177Lu]Lu-pentixather in patients with relapsed/refractory AL (including both acute myeloid leukemia and acute lymphoblastic leukemia). Methods: PENTILULA is an investigator-initiated, first-in-human, prospective phase 1/2 study based on a standard 3 + 3 dose-escalation design with 5 levels and 3–6 patients per level. Key inclusion criteria include patients with relapsed/refractory AL with CXCR4-positive leukemic cells. The primary endpoint is the incidence and evaluation of dose-limiting toxicities (DLTs) and determination of the MTD. DLTs will be assessed 4–6 wk after RPT and include grade 3 or higher nonhematologic toxicity, prolonged grade 4 pancytopenia with hypocellular bone marrow, and excessive renal or hepatic radiation absorbed dose. The MTD is defined as the highest level at which fewer than one third of patients experience a DLT. In a subset of patients, [68Ga]Ga-pentixafor PET/MRI will be performed to explore the predictive value of theranostic PET imaging on CXCR4 expression, dosimetry, and treatment response. Conclusion: This first-in-human clinical study is ongoing, having reached the fifth and final activity level. [177Lu]Lu-pentixather is being used to definitively establish the MTD and preliminary efficacy of this CXCR4-targeted approach in this high-risk population with limited therapeutic options.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
张天泽完成签到,获得积分10
刚刚
1秒前
azu发布了新的文献求助10
1秒前
1秒前
Jun的应助被KKH采纳,获得10
1秒前
yuan发布了新的文献求助10
2秒前
正在发布了新的文献求助10
2秒前
风趣梦松完成签到,获得积分10
3秒前
kklove的应助被嘻嘻哈哈采纳,获得70
3秒前
研友_VZG7GZ的应助被自信的煎饼采纳,获得10
3秒前
李健的小迷弟的应助被荔枝采纳,获得10
3秒前
科研通AI2S的应助被荔枝采纳,获得10
3秒前
3秒前
weiyichen发布了新的文献求助10
3秒前
搞怪冰岚完成签到,获得积分10
3秒前
3秒前
4秒前
5秒前
5秒前
5秒前
5秒前
5秒前
淡然的含卉的应助被马少兴采纳,获得10
5秒前
安详烤鸡完成签到 ,获得积分10
5秒前
dyq发布了新的文献求助10
5秒前
CipherSage的应助被嘻嘻采纳,获得10
6秒前
6秒前
lkl完成签到 ,获得积分10
6秒前
7秒前
yaxianzhi完成签到,获得积分10
7秒前
8秒前
极限001的应助被纯情的阁采纳,获得100
8秒前
Crazy_Diamond的应助被纯情的阁采纳,获得100
8秒前
8秒前
无极微光的应助被梦之瓜采纳,获得20
8秒前
8秒前
8秒前
生性不爱说话完成签到,获得积分10
9秒前
哈哈哈aaao发布了新的文献求助10
9秒前
LSD发布了新的文献求助10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163922
求助须知:如何正确求助?哪些是违规求助? 9557995
关于积分的说明 21743022
捐赠科研通 7754548
什么是DOI,文献DOI怎么找? 3428401
关于科研通互助平台的介绍 2553053
邀请新用户注册赠送积分活动 2473008